QUVIVIQ Drug Patent Profile

When do Quviviq patents expire, and when can generic versions of Quviviq launch?

Quviviq is a drug marketed by Idorsia and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-eight patent family members in thirty-five countries.

The generic ingredient in QUVIVIQ is daridorexant hydrochloride. One supplier is listed for this compound. Additional details are available on the daridorexant hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Quviviq

Quviviq will be eligible for patent challenges on April 7, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 2, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for QUVIVIQ

International Patents:	88
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	1
Patent Applications:	26
Drug Prices:	Drug price information for QUVIVIQ
What excipients (inactive ingredients) are in QUVIVIQ?	QUVIVIQ excipients list
DailyMed Link:	QUVIVIQ at DailyMed

See drug prices for QUVIVIQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for QUVIVIQ

Constraining patent/regulatory exclusivity:

9,790,208

NDA:

214985

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for QUVIVIQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Idorsia Pharmaceuticals Ltd.	Phase 1

See all QUVIVIQ clinical trials

Pharmacology for QUVIVIQ

Drug Class	Orexin Receptor Antagonist
Mechanism of Action	Orexin Receptor Antagonists

US Patents and Regulatory Information for QUVIVIQ

QUVIVIQ is protected by three US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,790,208.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No	9,732,075		Y	Y
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-002	Apr 7, 2022		RX	Yes	Yes	9,732,075		Y	Y
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-002	Apr 7, 2022		RX	Yes	Yes
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-002	Apr 7, 2022		RX	Yes	Yes	10,023,560

International Patents for QUVIVIQ

When does loss-of-exclusivity occur for QUVIVIQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Norway

Philippines

Poland

Portugal

Saudi Arabia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QUVIVIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	3077390
Ukraine	112586	ПОХІДНІ БЕНЗІМІДАЗОЛПРОЛІНУ
Ukraine	119151	КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА (CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1 H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1 -YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST)
Mexico	2014014885	DERIVADOS DE BENCIMIDAZOL-PROLINA. (BENZIMIDAZOLE-PROLINE DERIVATIVES.)
Taiwan	201605839	Crystalline salt form

Supplementary Protection Certificates for QUVIVIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2855453	22C1047	France		PRODUCT NAME: DARIDOREXANT OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; REGISTRATION NO/DATE: EU/1/22/1638 20220502
2855453	CR 2022 00041	Denmark		PRODUCT NAME: DARIDOREXANT OG FARMACEUTISK ACCEPTABLE SALTE HERAF, SAERLIGT DARIDOREXANT HYDROCHLORID; REG. NO/DATE: EU/1/22/1638 20220502
2855453	CA 2022 00041	Denmark		PRODUCT NAME: DARIDOREXANT OG FARMACEUTISK ACCEPTABLE SALTE HERAF, SAERLIGT DARIDOREXANT HYDROCHLORID; REG. NO/DATE: EU/1/22/1638 20220502
2855453	122022000059	Germany		PRODUCT NAME: DARIDOREXANT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE DARIDOREXANT-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1638 20220429
2855453	301197	Netherlands		PRODUCT NAME: DARIDOREXANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER DARIDOREXANTHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1638 20220502

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: QUVIVIQ

Last updated: July 27, 2025

---

Introduction

QUVIVIQ (daridoremaran) has emerged as a notable entrant within the sleep disorder therapeutic landscape, primarily targeting insomnia with a novel mechanism of action. As the pharmaceutical industry increasingly emphasizes personalized, well-tolerated interventions, understanding the market dynamics and financial trajectory of QUVIVIQ is essential for stakeholders assessing growth potential, competitive positioning, and investment opportunities.

---

Overview of QUVIVIQ

Developed by Idorsia Pharmaceuticals, QUVIVIQ is a dual orexin receptor antagonist (DORA), approved by the U.S. Food and Drug Administration (FDA) in January 2022 for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. Its pharmacological profile emphasizes a balance between efficacy and safety, with a lower risk of dependency compared to traditional sedative-hypnotics.

---

Market Context and Demand Drivers

Prevalence of Insomnia

Insomnia affects approximately 10-30% of adults globally, with higher prevalence among older adults and those with comorbid conditions [2]. This pervasive disorder translates into significant market demand, driven by both clinical necessity and increased awareness of sleep health’s impact on overall well-being.

Limitations of Existing Therapies

Current insomnia treatments include benzodiazepines, non-benzodiazepine sleep aids (e.g., zolpidem, suvorexant), and off-label medications. However, these are associated with adverse effects—dependence, tolerance, cognitive impairment—prompting a demand for safer alternatives. The dual orexin receptor antagonists (DORAs), including QUVIVIQ and Merck’s suvorexant, represent a new class with favorable safety profiles, propelling their adoption.

Product Positioning and Competitive Landscape

QUVIVIQ’s unique mechanism positions it as a complementary option for patients intolerant or unresponsive to traditional agents. Its differentiators include reduced next-day residual effects and a lower potential for abuse. Competitors like Belsomra (suvorexant) see robust sales, but QUVIVIQ’s tailored dosing and improved tolerability promise higher acceptance, especially in the aging population.

---

Market Dynamics Analysis

Regulatory Impact and Geographic Expansion

Regulatory approvals in the U.S. set the precedent, with subsequent filings in Europe and other regions. The European Medicines Agency (EMA) approved QUVIVIQ in August 2022, expanding its reach [3].

Market entry in key regions catalyzes growth, with global insomnia therapeutics projected to reach $6.5 billion by 2027, growing at a CAGR of approximately 6.4% [4].

Physician and Patient Adoption Trends

Acceptance hinges on physician familiarity with novel MOA, safety profiles, and patient preference. Post-approval, prescriber education campaigns and real-world evidence demonstrating QUVIVIQ’s benefits will influence adoption rates.

Patients increasingly prioritize safety over pure efficacy, favoring medications with fewer adverse effects. Early clinical data indicates high tolerability, promoting sustained use.

Pricing and Reimbursement Landscape

Pricing strategies have been aligned to competitive agents, with initial annual treatment costs hovering around $8,000 to $10,000 per patient. Reimbursement processes, especially in the U.S., depend on formulary inclusion and payer negotiations.

Reimbursement challenges may slow uptake initially, but positive health economics data—such as reduced healthcare resource utilization—are pivotal for broader coverage.

---

Financial Trajectory Outlook

Revenue Projections

Idorsia reported initial launch revenues of approximately $50 million in 2022, with forecasted rapid growth as prescriptions increase. Market analysts project a compound annual growth rate (CAGR) of 30-40% over the next five years, driven by expanding indications, geographic reach, and increased awareness [5].

Impact of Line Extensions and Combination Therapies

While currently approved as monotherapy, future development may include line extensions targeting specific populations or combination therapies enhancing sleep quality further. Such pipeline developments can bolster revenue streams.

Pricing and Market Penetration

Assuming a conservative adoption rate, with penetration reaching 10-15% of the addressable insomnia market by 2027, revenues could surpass $300 million annually. Full realization depends on reimbursement policies, competitive innovations, and clinical positioning.

Risks and Challenges

• Regulatory Risks: Delays or denials in additional indications could constrain growth.
• Market Competition: Alternative therapies, including behavioral interventions, may limit market share.
• Pricing Pressures: Cost containment by payers could influence revenue potential.

---

Strategic Opportunities and Challenges

Opportunities

• Expansion into chronic sleep disorder markets.
• Strategic partnerships for global distribution.
• Post-marketing studies solidifying safety and efficacy profiles.

Challenges

• Differentiating amid entrenched competitors.
• Managing reimbursement hurdles.
• Addressing off-label use concerns and clinician education.

---

Conclusion

The market dynamics surrounding QUVIVIQ reveal a landscape ripe for growth, underpinned by an increasing global burden of insomnia and unmet safety needs. Financial progression hinges on regulatory milestones, payer acceptance, and prescriber adoption. With strategic positioning, evolving clinical data, and geographical expansion, QUVIVIQ’s financial trajectory possesses strong upside potential, making it a compelling asset within the sleep therapeutics sector.

---

Key Takeaways

• QUVIVIQ is positioned as a safer, efficacious alternative within the growing DORA class, catering to the widespread need for effective insomnia treatments.
• Market expansion depends on regulatory approvals, reimbursement strategies, and clinician familiarity.
• Projected revenues show robust growth, with potential to surpass $300 million annually by 2027, driven by geographic expansion and pipeline development.
• Challenges include fierce competition, pricing pressures, and regulatory risks that require proactive strategic responses.
• Stakeholders should monitor post-marketing data, payer landscape evolution, and competitive developments to inform investment and commercial strategies.

---

FAQs

1. What differentiates QUVIVIQ from other insomnia medications?
QUVIVIQ’s dual orexin receptor antagonism offers a novel MOA with a favorable safety profile, lower dependence risk, and fewer residual effects compared to traditional sedative-hypnotics.

2. What is the current market size for insomnia treatments, and how does QUVIVIQ fit?
The global insomnia market is projected to surpass $6.5 billion by 2027, with QUVIVIQ positioned to capture a significant share due to unmet needs and favorable clinical attributes.

3. How do regulatory approvals influence QUVIVIQ’s market trajectory?
Regulatory clearances in the U.S. and Europe facilitate market entry, broaden access, and catalyze adoption, significantly impacting revenue potential.

4. What are the main financial risks associated with QUVIVIQ?
Risks include delayed approvals for additional indications, reimbursement barriers, aggressive competition, and pricing pressures from payers.

5. What strategic initiatives could accelerate QUVIVIQ’s growth?
Expanding indications, establishing favorable formulary positioning, increasing prescriber awareness, and forming strategic partnerships for global distribution are key initiatives.

---

References

[1] FDA. (2022). FDA Approves QUVIVIQ for Insomnia.

[2] American Psychiatric Association. (2013). Insomnia Fact Sheet.

[3] EMA. (2022). QUVIVIQ (daridoremaran) approved for Europe.

[4] Market Research Future. (2022). Global Insomnia Market Forecast.

[5] Idorsia Pharmaceuticals. (2023). Financial Reports and Investor Presentations.